Xenetic Biosciences, Inc. · NASDAQ:XBIO
Xenetic Biosciences — Investor Presentation (September 2021)
28 slides from Xenetic Biosciences's investor presentation, Sep 13, 2021
Slide 1: Expanding the Potential of CAR T Cell Therapy
Expanding the Potential of CAR T CellTherapy NASDAQ:XBIO xeneticbio.com InvestorPresentation September 2021
Slide 2: Forward-Looking Statements
Forward-LookingStatements Thispresentationcontainsforward-lookingstatementsthatweintendtobesubjecttothesafeharborprovisionsofthePrivateSecuritiesLitigationReform Act of1995.Allstatementscontainedinthispresentationotherthanstatementsofhistoricalfactsmayconstituteforward-lookingstatementswithinthe mea
Slide 3: Investment Highlights
InvestmentHighlights 3 Opportunity ? Targeting tumor-specific antigens that are independent of CD19 or other antigens common to allB-Cells ? Advancing towards Phase 1study ? Lead program targeting $7 billion B-Cell malignancymarket 1 Leveraging OutsourcedRelationships 1: Triangle Insights: Company C
Slide 4: Team with Proven Expertise
Team with ProvenExpertise Jeffrey F.Eisenberg Chief Executive Officer &Director Life Sciences executive with over 20 years of successful track record in value creation in both private and public companies; former CEO of Noven Pharmaceuticals, responsible for leading 2 product launches and Noven’s No
Slide 5: Scientific Advisory Board with Extensive Cell Therapy Development Experience
Scientific Advisory Board withExtensive Cell Therapy Development Experience 5 Dr. MatthewFrigault Medical Oncologist in the Hematologic Malignancy Program at theMassachusetts General Hospital Cancer Center, as well as Assistant Director of the Cellular Immunotherapy Program; serves as Instructor at
Slide 6: Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach
Personalized CAR T platform targetingcancers with a patient-and tumor-specificapproach 6 Platform
Slide 7: Lymphoma
Lymphoma 7 Group of blood cancers that developfrom lymphocytes located in the lymphsystem Two Types ofLymphocytes B-Cells T-Cells Produce and secrete antibodies in the form of B-Cell receptors (BCR) which selectively target a givenantigen Helper T-Cells: modulate the function of B-Cells and killerT-
Slide 8: B-Cells and Tumor Growth
B-Cells and TumorGrowth 8 Tumor develops with the unique BCRcloneB-Cell receptor (BCR) vsCD19 Current commercial therapies target the common CD19 receptor that is present on allB-Cells CD19 CD19 Normal B-Cells Malignant B-Cell Proliferation (Retains UniqueBCR) >1,000,000,000 Unique B-CellClones CD19
Slide 9: Anti-CD19 CAR T Therapies Work…
Anti-CD19 CAR T TherapiesWork… 9 1:https://my.clevelandclinic.org/health/treatments/17726-car-t-cell-therapy/risks--benefits; 2:https://www.fiercepharma.com/pharma/ash-gilead-touts-astounding-yescarta-survival-results-at-3-years Current CAR T therapies target both normal and malignantB-Cells >80% co
Slide 10: …But There Is Need For Improvement
…But There Is Need ForImprovement 10 CAR T Relapse: lack of durableresponse T-Cell Exhaustion: progressive loss of CART effectorfunction ToxicityProblems: Cytokine Release Syndrome(CRS) Neurotoxicity B-Cell Aplasia: elimination of allB-Cells Significant shortcomings with currently approved CAR Tther
Slide 11: CD19 Escape: Emergence of CD19- Tumor Cells
CD19 Escape: Emergence of CD19 - Tumor CellsResulting from Anti-CD19 Treatments, including CART 11 Estimated percentage of patients who relapse due to CD19escape 2 ~10-50% Ofpatientshavealowercount ofCD19-positiveB-Cellsdueto priortherapies 2 10-15% Incidence of CD19 escape is expected to increase w
Slide 12: Targets the Tumor's Unique BCR
Targets the Tumor’s UniqueBCR 12 Ability to address the CD19 escapephenomenon Malignant B-Cell Malignant B-Cellwith CD19Escape UniqueBCR CD19 UniqueBCR CD19 Anti-CD19 CART
Slide 13: Only Targets Malignant B-Cells
Only Targets MalignantB-Cells Potential for increased efficacy, safety and tolerability over currently approved CAR Ttherapies Malignant B-CellTargeted 13 Unique BCR Presents Tumor-SpecificTarget OnlyMalignant B-CellsEliminated NormalB-Cells areSpared CD19 CD19 UniqueBCR UniqueBCR NormalB-Cell NotTa
Slide 14: Selectively Kill Raji B-Cell Lines Expressing Target BCRs
Selectively Kill Raji B-CellLines Expressing TargetBCRs 14 Raji B-cells (Raji-FL1, Raji-FL2 and Raji-FL3) expressing BCRs from the respective FLlymphomas were lysed by activated human CD8+ T cells bearing a corresponding cyclopeptide-CARconstruct 1 Human CD8+ T cells were transduced with Lentiviral
Slide 15: XCART Addresses Need in Current Lymphoma Treatment Paradigm
XCART Addresses Need in CurrentLymphoma TreatmentParadigm 15 Follicular Lymphoma(FL) ~14,000/year USIncidence 1 1 st LineTherapy: ~11,000Patients 2 nd LineTreatment: ~5,000Patients XCARTOpportunity: 3 rd LineTreatment ~3,000Patients Diffuse Large B-Cell Lymphoma(DLBCL) ~26,000/year USIncidence 1 1 s
Slide 16: Leveraging Outsourced Relationships
Leveraging OutsourcedRelationships Expediting Development Pipeline with Proven Expertise andCapabilities 16
Slide 17: Driving Development Through Outsourced Relationships
Driving DevelopmentThrough OutsourcedRelationships 17 Commencing clinical manufacturingprocess ? Ongoing exploratorypatient biopsy study in EasternEurope Seeking U.S.FDA INTERACTmeeting File U.S.IND Commence Phase 1Trial Upcoming PotentialMilestones Access to ManufacturingSuites Established CMC and
Slide 18: Exploratory Patient Biopsy Study
Exploratory Patient BiopsyStudy 18 Evaluating XCART platform in biopsy and blood samples from B-Cell NHLpatients 1 Validate upstream workflow for isolating and screening tumor-specificneoantigens 2 Identify and characterize potential tumor-specific CARconstructs 3 Study has provided materials and me
Slide 19: Collaborators
Collaborators 19 Additional collaborations advancing XCART toward IND-enablingstudies AcademicCollaborators (One of the original developers of the XCARTplatform) Design and implementation of the preclinical developmentprogram Method development activities supporting process development for clinicalm
Slide 20: Academic Collaborator Pharmsynthez
AcademicCollaborator 20 PHARMSYNTHEZ Research organization coordinating activities with partnered academic institutions in EasternEurope Supports optimization of overall XCARTworkflow Access to clinical centers and B-Cell non-Hodgkin lymphoma (NHL)patients Potential to conduct Phase 1trial P1
Slide 21: PolyXen PSA Technology Platform Enables Next Generation Biologic Drugs
PolyXen® PSA TechnologyPlatform Enables Next Generation BiologicDrugs 21
Slide 22: PolyXen: Next Generation Half-Life Extension Platform Technology
PolyXen: Next GenerationHalf-Life Extension PlatformTechnology 22 Polysialylation employs the biological polymer polysialic acid (PSA) to modulate the PK and PD profiles of proteindrugs Clinically demonstrated to extend half-life of therapeuticproteins Applicable to franchise extensionsas well as ca
Slide 23: Financial Snapshot
FinancialSnapshot NASDAQ:XBIO 23 Cash runway expected to fund Company through XCART INDfiling SharesOutstanding 2 ~9.7M Market Cap 1 ~$26M AverageVolume 1 ~10.1M 1: As of September 8,2021 2: As of August 6,2021 CashBalance $9.3M as of June 30,2021 Does not include net proceedsfrom $12.5 million priv
Slide 24: Investment Summary
InvestmentSummary 24 Advancing XCART program throughpreclinical development into the clinic as quickly aspossible Positioning to have a transformative impact in the CAR Tspace $7B 1: Triangle Insights: Company Commissioned MarketReport PolyXen Truly differentiated CAR Ttechnology Lead program target
Slide 25: Expanding the Potential of CAR T Cell Therapy
Expanding the Potential of CAR T CellTherapy NASDAQ:XBIO xeneticbio.com JTC Team,LLC. T:833-475-8247 xbio@jtcir.com
Slide 26: Appendix
Appendix 26
Slide 27: CAR T Therapies Expected to Hold Significant Revenue Share by 2026
CAR T Therapies Expected toHold Significant Revenue Share by 2026 27 US revenue for top products* targeting key B-Cellmalignancies Product Company Mechanism First Approval^ Relevant Indications 2026 Revenue CAGR (2019-2026) Polivy CD79B antibody 06/2019DLBCL DLBCL $805M 48% Kymriah CD19 CART 08/2017
Slide 28: Current CAR T Therapies Are Priced Over $300,000
Current CAR T TherapiesAre Priced Over$300,000 28 $41K $373K DLBCL TreatmentPricing $373K $0 $100 $200 $300 $400 W A C ( $ K ) p e r T r e a t m e n t C o u r s e Type ofTherapy MonoclonalAntibody CellTherapy ApprovedIndications NHL (Including CLL andDLBCL) LBCL (including DLBCLpatients) ALL,LBCL (i
Xenetic Biosciences — Investor Presentation (September 2021) on 6ix